ライフサイエンスコーパス: nicotinic agonist

1 restored the antinociceptive effects of the nicotinic agonist.

2 pinal excitatory amino acids released by the nicotinic agonist.

3 ics common with channel activity elicited by nicotinic agonists.

4 to modulate receptor activation by selected nicotinic agonists.

5 ding site that is distinct from the site for nicotinic agonists.

6 ponse data for epibatidine and several other nicotinic agonists.

7 hibit a high affinity for nicotine and other nicotinic agonists.

8 uid (aCSF) and found that application of the nicotinic agonist 1,1-dimethyl-4-phenyl-piperazinium iod

9 of chromaffin vesicles was increased by the nicotinic agonist 1,1-dimethyl-4-phenyl-piperazinium iod

10 cell line are functional, and in response to nicotinic agonists, 86Rb+ efflux was increased to levels

11 bserved in 84% of patches (n = 118) when the nicotinic agonists acetylcholine (1-100 microM), carbamy

12 Three different nicotinic agonists, ACh, nicotine, and dimethylphenylpip

13 easome activity was significantly blunted by nicotinic agonist administration in vivo.

14 Treatment of human kidney cells with nicotinic agonists, an NFkappaB inhibitor (Bay11), or a

15 ntary treatment of 17 beta-estradiol and the nicotinic agonist anabasine resulted in the translocatio

16 The nicotinic agonist anatoxin-a (AnTx) evoked monophasic [(

17 e) anabaseine (DMXB-A) is a partial alpha(7)-nicotinic agonist and can be taken orally.

18 t involved in specific interactions with the nicotinic agonist and that they affect the activation of

19 sensitive to simulation of egg-laying by the nicotinic agonist and was accompanied by a promoter-inde

20 we compared up-regulation by three different nicotinic agonists and a competitive antagonist of sever

21 or binding pose that differs from classical nicotinic agonists and antagonists and from the previous

22 cooperative fashion, not seen for classical nicotinic agonists and antagonists.

23 kinetics of whole-cell current responses to nicotinic agonists and are more sensitive to the beta2 s

24 Mutual occlusion of the effects of nicotinic agonists and ATP analogues were also observed

25 tameric oligomers in which binding sites for nicotinic agonists and competitive antagonists are found

26 be produced by a variety of drugs, including nicotinic agonists and competitive antagonists, but prev

27 competition studies reveal high affinity for nicotinic agonists and lower affinity for nicotinic anta

28 of GABA in the SpL can be regulated by both nicotinic agonists and mu opioids.

29 ctions between the hydrogen bond acceptor of nicotinic agonists and the complementary subunit backbon

30 An alpha7 nicotinic agonist appears to have positive effects on ne

31 of inward currents induced by 1 s pulses of nicotinic agonists, applied at 30 s intervals, gradually

32 The alpha7 nicotinic agonist AR-R17779 inhibited phosphorylation of

33 he predominant effects of nicotine and other nicotinic agonists are related to desensitization of the

34 esults support previous work suggesting that nicotinic agonists are viable as treatments for adult AD

35 d that the neuroprotective actions of alpha7 nicotinic agonists arise from activation of receptors an

36 This indicates chronic exposure to nicotinic agonist as a potential pharmacological interve

37 nique binding mode for the cationic amine of nicotinic agonists at the alpha7 receptor.

38 placebo-controlled double-blind trial of the nicotinic agonist AZD3480 (also termed TC-1734) at doses

39 oes not interfere with the occupation of the nicotinic agonist binding site by ACh, carbachol, or cho

40 hat physostigmine does not interact with the nicotinic agonist binding site.

41 In the presence of nicotinic agonists, Ca2+i responses were transient.

42 Spinal administration of nicotinic agonists can produce both hyperalgesic and ana

43 d by benzimidazole, macrocyclic lactone, and nicotinic agonist classes of anthelminthic drugs in the

44 Nicotinic agonists decreased evoked quantal output, but

45 -2 (50 and 500 units/well, respectively), or nicotinic agonist dimethylphenylpiperazinium (10 microM,

46 lso showed higher seizure sensitivity to the nicotinic agonist epibatidine, but not to the GABA(A) re

47 no effect on sensitivity to the nonselective nicotinic agonist epibatidine.

48 Occupation by nicotinic agonists, epibatidine and lobeline, and nicoti

49 Even high-dose nicotinic agonists failed to overcome the inhibition by

50 human macrophages and suggest that selective nicotinic agonists for the alpha7nAChR might have therap

51 the nicotinic stimulation had ceased and the nicotinic agonist had been washed away.

52 n to slow channel closing in the presence of nicotinic agonists had a similar effect in the presence

53 Clinical trials of nicotinic agonists have been mixed, underscoring the nee

54 Pharmacophore models for nicotinic agonists have been proposed for four decades.

55 In general, nicotinic agonists have been shown to improve memory, an

56 Two types of structurally similar nicotinic agonists have very different biological and ph

57 n-deficit/hyperactivity disorder (ADHD), and nicotinic agonists improve attention across preclinical

58 atidine has been shown to be the most potent nicotinic agonist in several neuronal nicotinic receptor

59 The rank ordering of potencies of the nicotinic agonists in displacing (+/-)-[3H]epibatidine b

60 the potentially novel therapeutic effects of nicotinic agonists in patients with AD.

61 Nicotinic agonists induce peak whole-cell current respon

62 The differences between nicotinic agonist induced catecholamine and serotonin re

63 ition within several hundred milliseconds of nicotinic agonist-induced fusion.

64 uced release of dopamine from PC12 cells and nicotinic agonist-induced hGH release from bovine adrena

65 activator, p25, led to a strong increase in nicotinic agonist-induced secretory responses.

66 Nicotinic agonist interactions with mollusk (Aplysia cal

67 Similar to other nicotinic agonists, intrathecal (-)-epibatidine elicits

68 hese data suggest that nicotine or selective nicotinic agonists may represent a useful treatment stra

69 It has been shown that the non-selective nicotinic agonist nicotine has an influence on auditory

70 Desensitizing effects of the nicotinic agonists nicotine and epibatidine were blocked

71 The occlusive effects of nicotinic agonists on ATP-gated currents were blocked by

72 estigate the short- and long-term effects of nicotinic agonists on GABAergic transmission.

73 eta2-nAChRs with characteristic responses to nicotinic agonists or antagonists.

74 f currents elicited by low concentrations of nicotinic agonists, or, at higher concentrations, channe

75 Carbachol and other nicotinic agonists produced marked increases in the freq

76 Classical nicotinic agonists show a 10-40-fold reduction in bindin

77 st action was specific to desensitization by nicotinic agonists, since catestatin did not block desen

78 igh levels of Ca2+, (ii) secretion caused by nicotinic agonist stimulation can be significantly enhan

79 Catecholamine secretion induced by other nicotinic agonists (such as epibatidine, anatoxin, or cy

80 ts on receptor activation by galantamine and nicotinic agonists, suggesting that the general features

81 DMXB-A, a nicotinic agonist that activates alpha(7)-nicotinic rece

82 ased on two disparate bound conformations of nicotinic agonists, thereby establishing an atypical con

83 th similar potency when triggered by several nicotinic agonists, though not by agents using other sec

84 opical application of either a muscarinic or nicotinic agonist to the exposed cortex, respectively, a

85 both proteasome activity and inflammation by nicotinic agonists to attenuate LPS-induced kidney injur

86 The binding of nicotinic agonists to cell-surface BgtRs was highly coop

87 ve and contribute directly to the ability of nicotinic agonists to evoke GABA release in these region

88 Consistent with these observations, nicotinic agonist treatment significantly decreased rena

89 These results suggest that nicotinic agonist treatments can ameliorate learning and

90 The rank order of potency for nicotinic agonists was as follows: epibatidine > nicotin

91 The Ca(2+) response to nicotinic agonists was markedly prolonged in cells from

92 TP analogues on inward currents generated by nicotinic agonists were blocked by the P2X receptor anta